Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to 325.44%.

  • Editas Medicine's EBITDA Margin rose 1073237400.0% to 325.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 428.71%, marking a year-over-year decrease of 586800.0%. This contributed to the annual value of 777.22% for FY2024, which is 5606700.0% down from last year.
  • Per Editas Medicine's latest filing, its EBITDA Margin stood at 325.44% for Q3 2025, which was up 1073237400.0% from 1440.58% recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's EBITDA Margin peaked at 39.9% during Q4 2023, and registered a low of 136952.38% during Q3 2022.
  • Its 5-year average for EBITDA Margin is 15270.04%, with a median of 940.09% in 2023.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -1363189600bps in 2022, then skyrocketed by 1360122900bps in 2023.
  • Editas Medicine's EBITDA Margin (Quarter) stood at 333.71% in 2021, then tumbled by -191bps to 970.72% in 2022, then soared by 96bps to 39.9% in 2023, then tumbled by -282bps to 152.24% in 2024, then plummeted by -114bps to 325.44% in 2025.
  • Its last three reported values are 325.44% in Q3 2025, 1440.58% for Q2 2025, and 1635.1% during Q1 2025.